Myriad Genetics, Inc. (MYGN): Price and Financial Metrics

MYGN POWR Grades

• MYGN scores best on the Growth dimension, with a Growth rank ahead of 83.26% of US stocks.
• The strongest trend for MYGN is in Growth, which has been heading up over the past 177 days.
• MYGN ranks lowest in Momentum; there it ranks in the 1st percentile.

MYGN Stock Summary

• Equity multiplier, or assets relative to shareholders' equity, comes in at 1.32 for MYRIAD GENETICS INC; that's greater than it is for merely 19.12% of US stocks.
• In terms of twelve month growth in earnings before interest and taxes, MYRIAD GENETICS INC is reporting a growth rate of 134.91%; that's higher than 89.11% of US stocks.
• Revenue growth over the past 12 months for MYRIAD GENETICS INC comes in at -3.36%, a number that bests just 20.07% of the US stocks we're tracking.
• If you're looking for stocks that are quantitatively similar to MYRIAD GENETICS INC, a group of peers worth examining would be ANGO, LIQT, LPTH, ITI, and NRDS.
• MYGN's SEC filings can be seen here. And to visit MYRIAD GENETICS INC's official web site, go to myriad.com.

MYGN Valuation Summary

• In comparison to the median Healthcare stock, MYGN's EV/EBIT ratio is 231.31% lower, now standing at -13.
• MYGN's price/sales ratio has moved down 3 over the prior 243 months.

Below are key valuation metrics over time for MYGN.

MYGN Growth Metrics

Its 3 year revenue growth rate is now at -17.84%.
• The 3 year net income to common stockholders growth rate now stands at -153.59%.
• Its 2 year net income to common stockholders growth rate is now at 94.47%.

MYGN's revenue has moved down $152,000,000 over the prior 33 months.

The table below shows MYGN's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	661.4	-108.5	-77.3
2022-06-30	672.3	-146	-17.6
2022-03-31	682.4	-100.1	-8.2
2021-12-31	690.6	18.2	-27.2
2021-09-30	684.4	13.7	-57.5
2021-06-30	662.3	-6.3	-97.3

MYGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• MYGN has a Quality Grade of C, ranking ahead of 61.95% of graded US stocks.
• MYGN's asset turnover comes in at 0.476 -- ranking 93rd of 681 Pharmaceutical Products stocks.
• CDXC, CEMI, and GERN are the stocks whose asset turnover ratios are most correlated with MYGN.

The table below shows MYGN's key quality metrics over time.